news

  • 14 February 2018
    Sienna Biopharmaceuticals announces first patient dosed in first-in-human trial of Topical SNA-125

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is designed to inhibit janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA, with minimal to no systemic exposure. JAK3 is a validated target in psoriasis, atopic dermatitis and pruritus. JAK3 is required for immune cell development, and inhibiting JAK3 blocks the signaling of key cytokines, such as interleukin-17A, or IL-17A, IL-17F, IL-2 and tumor necrosis factor-alpha, or TNF-α, which results in a reduction in the severity of autoimmune and inflammatory diseases in which those cytokines play a pivotal role. TrkA is the high affinity receptor for nerve growth factor, or NGF, a known mediator of neurogenic inflammation and itch associated with psoriasis. This multicenter, randomized, double-blind, placebo- and comparator-controlled, intra-individual trial will evaluate the safety, tolerability and efficacy of SNA-125 compared to vehicle and other reference formulations in approximately 15 patients with chronic psoriasis.

    “We are excited to now have two product candidates from our Topical by Design™ platform in the clinic,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “This week, we dosed our first patient in the SNA-125 proof-of-concept trial for psoriasis and expect to report top-line data in the third quarter of 2018. Last quarter, we dosed our first patient in the SNA-120 Phase 2b clinical trial for pruritus and the associated underlying psoriasis and expect to report top-line data in the first half of 2019. Soon, we plan to initiate the SNA-125 proof-of-concept trial for atopic dermatitis and expect those data in the second half of 2018.”

    “In nonclinical studies to date, SNA-125 has demonstrated strong inhibition of JAK3 and TrkA as well as cytokine modulation similar to tofacitinib,” said Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer of Sienna. “JAK3 is known to significantly reduce the severities of psoriasis, atopic dermatitis and associated pruritus, though oral JAK3 inhibitors are not particularly well tolerated. Our goal with this proof-of-concept trial, using the validated psoriasis plaque test, is to gain early clinical insight into the safety, tolerability and efficacy of SNA-125 as a topical treatment for psoriasis.”